Company intelligence / Profile preview

Oviva Therapeutics

New York, New York, United Statesovivatx.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Oviva Therapeutics was developing OVI-586, a first-in-class therapeutic designed to enhance women's health span by extending ovarian function. The company was acquired by Granata Bio on April 29, 2025.

Therapeutic areas: Women's Health
Modalities: First-in-class therapeutics
Industry: Biotech

Partnerships

Cambrian BioPharma

Beyond the preview

Go deeper on Oviva Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oviva Therapeutics.

Explore the full profile